Icelandic firm Alvotech (Nasdaq: ALVO) and marketing partner German drugmaker STADA Arzneimittel (SAZ: Xetra) today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT04, Alvotech’s proposed biosimilar to Stelara (ustekinumab).
The companies anticipate that the EMA could give recommend approving a marketing authorization for AVT04 as soon as in the second half of 2023.
Stelara is marketed by US healthcare giant Johnson & Johnson’s (NYSE: JNJ) subsidiary Janssen Pharmaceutical for a variety of autoimmune diseases including ulcerative colitis and psoriasis. The drug generated global sales of $9.7 billion in full-year 2022, up 6.5% on 2021.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze